Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial
Open Access
- 16 July 2018
- journal article
- research article
- Published by Hindawi Limited in Pediatric Diabetes
- Vol. 19 (7), 1263-1270
- https://doi.org/10.1111/pedi.12724
Abstract
Background Insulin degludec/insulin aspart (IDegAsp) is a fixed soluble co‐formulation of basal and bolus insulin. Objective To evaluate efficacy and safety of IDegAsp in pediatric patients with type 1 diabetes (T1D). Subjects Children and adolescents (aged 1–95%CI (–0.45 mmol/mol [–2.51; 1.60]95%CI), confirming non‐inferiority. There were no significant differences between treatment groups in fasting or self‐measured plasma glucose. Confirmed hypoglycemia rates did not significantly differ between groups. There was a significant reduction in basal and total insulin dose with IDegAsp+IAsp versus IDet+IAsp (post hoc analysis). Mean number of injections/day was 3.6 and 4.9 with IDegAsp+IAsp and IDet+IAsp, respectively (post hoc analysis). A non‐significant higher rate of severe hypoglycemia was observed with IDegAsp+IAsp versus IDet+IAsp. The most frequent adverse events in both groups were hypoglycemia, headache and nasopharyngitis. Conclusions IDegAsp+IAsp was non‐inferior to IDet+IAsp regarding HbA1c, had similar hypoglycemia rates and required fewer injections.Keywords
Funding Information
- Novo Nordisk
This publication has 24 references indexed in Scilit:
- Insulin analogues in children with Type 1 diabetes: a 52‐week randomized clinical trialDiabetic Medicine, 2012
- Correlates of Insulin Injection OmissionDiabetes Care, 2010
- References for growth and pubertal development from birth to 21 years in Flanders, BelgiumAnnals of Human Biology, 2009
- Assessment and management of hypoglycemia in children and adolescents with diabetesPediatric Diabetes, 2009
- Assessment and monitoring of glycemic control in children and adolescents with diabetesPediatric Diabetes, 2009
- Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetesDiabetic Medicine, 2007
- Unique Challenges for Pediatric Patients With DiabetesDiabetes Spectrum, 2005
- Lower within‐subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2004
- Neurocognitive Correlates of Type 1 Diabetes Mellitus in ChildhoodChild Neuropsychology, 2004
- Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms.JCI Insight, 1987